Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARRY-403, glucokinase activator · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| ARRY-403 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ARRY-403, glucokinase activator; oral | DRUG | multiple dose, escalating |
| Placebo; oral | DRUG | matching placebo |
Key Inclusion Criteria: * Male or female (females must be of non-childbearing potential), between the ages of 18 and 70 years, inclusive. * Diagnosis of Type 2 diabetes. * Fasted C-peptide value ≥ 0.8 ng/mL. * HbA1c ≥ 6.5% and ≤ 10.0% for monotherapy cohorts (study drug only) or HbA1c ≥ 7.5% and ≤ ...
Top 13 of 24 competitors
ARRY-403 is an investigational oral small molecule being studied for the treatment of Type 2 Diabetes. It was evaluated in Phase 1 clinical trials in adults with Type 2 Diabetes in the United States. It is not approved for any indication and remains in clinical development.
ARRY-403 is a glucokinase activator, a small molecule that acts on the glucokinase enzyme. Glucokinase plays a role in glucose sensing and regulation, and activating it is the intended mechanism for lowering blood glucose in Type 2 Diabetes. The drug is orally administered.
ARRY-403 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the Phase 1 clinical studies of the compound in patients with Type 2 Diabetes.
ARRY-403 is in Phase 1 clinical development. Two Phase 1 trials have been completed, and no trials are currently active. The drug is investigational and has not been approved by the FDA for Type 2 Diabetes or any other indication.
ARRY-403 has been studied in two completed Phase 1 trials: NCT00952198, which enrolled 128 patients with Type 2 Diabetes, and NCT00859755, which enrolled 41 patients with Type 2 Diabetes. Both were conducted in the United States in adults aged 18 years and older.
Yes. ARRY-403 and ARRY-403, glucokinase activator refer to the same investigational oral compound. The longer name describes its mechanism as a glucokinase activator, while ARRY-403 is the compound identifier used in its clinical trial listings for Type 2 Diabetes.